Discontinuation of statins in routine care settings: a cohort study
- PMID: 23546564
- PMCID: PMC3692286
- DOI: 10.7326/0003-4819-158-7-201304020-00004
Discontinuation of statins in routine care settings: a cohort study
Abstract
Background: Systematic data on discontinuation of statins in routine practice of medicine are limited.
Objective: To investigate the reasons for statin discontinuation and the role of statin-related events (clinical events or symptoms believed to have been caused by statins) in routine care settings.
Design: A retrospective cohort study.
Setting: Practices affiliated with Brigham and Women's Hospital and Massachusetts General Hospital in Boston.
Patients: Adults who received a statin prescription between 1 January 2000 and 31 December 2008.
Measurements: Information on reasons for statin discontinuations was obtained from a combination of structured electronic medical record entries and analysis of electronic provider notes by validated software.
Results: Statins were discontinued at least temporarily for 57 292 of 107 835 patients. Statin-related events were documented for 18 778 (17.4%) patients. Of these, 11 124 had statins discontinued at least temporarily; 6579 were rechallenged with a statin over the subsequent 12 months. Most patients who were rechallenged (92.2%) were still taking a statin 12 months after the statin-related event. Among the 2721 patients who were rechallenged with the same statin to which they had a statin-related event, 1295 were receiving the same statin 12 months later, and 996 of them were receiving the same or a higher dose.
Limitations: Statin discontinuations and statin-related events were assessed in practices affiliated with 2 academic medical centers. Utilization of secondary data could have led to missing or misinterpreted data. Natural-language-processing tools used to compensate for the low (30%) proportion of reasons for statin discontinuation documented in structured electronic medical record fields are not perfectly accurate.
Conclusion: Statin-related events are commonly reported and often lead to statin discontinuation. However, most patients who are rechallenged can tolerate statins long-term. This suggests that many of the statin-related events may have other causes, are tolerable, or may be specific to individual statins rather than the entire drug class.
Primary funding source: National Library of Medicine, Diabetes Action Research and Education Foundation, and Chinese National Key Program of Clinical Science.
Figures
Comment in
-
Statin discontinuation and intolerance: the challenge of lifelong therapy.Ann Intern Med. 2013 Apr 2;158(7):562-3. doi: 10.7326/0003-4819-158-7-201304020-00010. Ann Intern Med. 2013. PMID: 23546569 No abstract available.
-
Prevention. Statin therapy--if at first you don't succeed..Nat Rev Cardiol. 2013 Jun;10(6):300. doi: 10.1038/nrcardio.2013.59. Epub 2013 Apr 16. Nat Rev Cardiol. 2013. PMID: 23591265 No abstract available.
-
Discontinuation of statins in routine care settings.Ann Intern Med. 2013 Jul 2;159(1):73-4. doi: 10.7326/0003-4819-159-1-201307020-00019. Ann Intern Med. 2013. PMID: 23817713 No abstract available.
-
Discontinuation of statins in routine care settings.Ann Intern Med. 2013 Jul 2;159(1):74. doi: 10.7326/0003-4819-159-1-201307020-00020. Ann Intern Med. 2013. PMID: 23817714 No abstract available.
-
Discontinuation of statins in routine care settings.Ann Intern Med. 2013 Jul 2;159(1):74-5. doi: 10.7326/0003-4819-159-1-201307020-00021. Ann Intern Med. 2013. PMID: 23817715 No abstract available.
-
Discontinuation of statins in routine care settings.Ann Intern Med. 2013 Jul 2;159(1):75-6. doi: 10.7326/0003-4819-159-1-201307020-00022. Ann Intern Med. 2013. PMID: 23817716 No abstract available.
Similar articles
-
Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study.Ann Intern Med. 2017 Aug 15;167(4):221-227. doi: 10.7326/M16-0838. Epub 2017 Jul 25. Ann Intern Med. 2017. PMID: 28738423
-
Summaries for patients. Discontinuation of statins.Ann Intern Med. 2013 Apr 2;158(7):I-40. doi: 10.7326/0003-4819-158-7-201304020-00001. Ann Intern Med. 2013. PMID: 23546582 No abstract available.
-
Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia.Ann Intern Med. 2020 Nov 17;173(10):806-812. doi: 10.7326/M20-4680. Epub 2020 Sep 22. Ann Intern Med. 2020. PMID: 32956601
-
State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications.Cardiovasc Drugs Ther. 2019 Oct;33(5):625-639. doi: 10.1007/s10557-019-06904-x. Cardiovasc Drugs Ther. 2019. PMID: 31773344 Review.
-
A systematic review and economic evaluation of statins for the prevention of coronary events.Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. doi: 10.3310/hta11140. Health Technol Assess. 2007. PMID: 17408535 Review.
Cited by
-
Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database.Pharmaceuticals (Basel). 2024 Oct 12;17(10):1365. doi: 10.3390/ph17101365. Pharmaceuticals (Basel). 2024. PMID: 39459005 Free PMC article.
-
Effectiveness of Coenzyme Q10 Supplementation in Statin-Induced Myopathy: A Systematic Review.Cureus. 2024 Aug 31;16(8):e68316. doi: 10.7759/cureus.68316. eCollection 2024 Aug. Cureus. 2024. PMID: 39350827 Free PMC article. Review.
-
Closing the Gaps in Care of Dyslipidemia: Revolutionizing Management with Digital Health and Innovative Care Models.Rev Cardiovasc Med. 2023 Dec 13;24(12):350. doi: 10.31083/j.rcm2412350. eCollection 2023 Dec. Rev Cardiovasc Med. 2023. PMID: 39077078 Free PMC article. Review.
-
Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease.Rev Cardiovasc Med. 2024 May 23;25(5):190. doi: 10.31083/j.rcm2505190. eCollection 2024 May. Rev Cardiovasc Med. 2024. PMID: 39076473 Free PMC article. Review.
-
Efficacy and safety assessment of traditional Chinese patent medicine for dyslipidemia: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis.Cardiovasc Diagn Ther. 2024 Jun 30;14(3):419-446. doi: 10.21037/cdt-24-146. Epub 2024 Jun 27. Cardiovasc Diagn Ther. 2024. PMID: 38975001 Free PMC article.
References
-
- Ford ES, Li C, Pearson WS, Zhao G, Mokdad AH. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol. 2010;140(2):226–35. - PubMed
-
- Zaninotto P, Head J, Stamatakis E, Wardle H, Mindell J. Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. J Epidemiol Community Health. 2009;63(2):140–6. - PubMed
-
- Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). Jama. 1986;256(20):2823–8. - PubMed
-
- Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–60. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical